{"text": "treatment of glaucoma amend rsa to read as follows treatment of glaucoma a optometrists seeking authorization to treat glaucoma shall complete at least hours of classroom education approved by the board incorporating epidemiology of the glaucomas genetics of the glaucomas anatomy physiology and mechanics of aqueous inflow and aqueous outflow optic nerve anatomy and pathophysiology neurotoxicity and neuroprotectants receptor biology pharmacology clinical use and toxic effects of alpha and beta adrenergic agents carbonic anhydrase inhibitors prostanoids and cholinergic agents b optometrists shall pass an examination approved by the board that covers the educational components listed in subparagraph a upon passage of such exam an optometrist shall have prescriptive authority during the clinical management period pursuant to rsa c the board shall waive the requirements of this paragraph and of paragraph ii for optometrists who have either graduated after or who have proof of months of credentialed privileges to treat glaucoma by the united states department of defense or department of veteran affairs or the national indian health service or who are certified by the american board of optometry verified by the board a to be authorized to initiate treatment of glaucoma for patients years of age or older a therapeutic pharmaceutical agent certified optometrist shall complete the educational requirements in paragraph i and provide evidence of written referrals and consultations with an ophthalmologist for purposes of this section glaucoma means primary glaucoma and ophthalmologist means a physician licensed under rsa with a specialty in ophthalmology the joint credentialing committee shall review evidence of glaucoma submitted pursuant to subparagraph b b except as provided in subparagraph i c or paragraph iii therapeutic pharmaceutical agent certified optometrists are required to provide evidence of successful collaborative treatment and of glaucoma patients up to of which may be established patients during a period of not less than months for each patient to ophthalmologists according to the following criteria a new or existing glaucoma patient is examined and diagnosed by the optometrist the optometrist develops a proposed treatment plan and forwards the plan with examination documentation to an ophthalmologist for consultation the ophthalmologist examines the patient and reviews the optometrist s examination documentation and proposed treatment plan the ophthalmologist optometrist and patient mutually agree to and document a treatment plan the optometrist shall consult with the ophthalmologist when any of the following occurs the patient s target pressure is not reached within days the patient is experiencing documented progression of optic nerve damage the patient develops documented and repeated progression of visual field loss or the patient develops or other secondary glaucoma and for each successfully glaucoma patient the optometrist and ophthalmologist shall complete a glaucoma credentialing reporting form and submit the form to the joint credentialing committee upon completion of the months of treatment the joint credentialing committee may waive or reduce the requirements of rsa i and ii for the following categories of optometrists a optometrists with a license and proof of practice for months treating glaucoma patients in another state that currently authorizes the treatment of glaucoma by optometrists or b optometrists who have proof of successful completion of a accredited optometric residency program or its equivalent upon certification to treat glaucoma patients a for a period of months optometrists shall consult with an ophthalmologist within days for each new glaucoma patient for confirmation of diagnosis and review of treatment plan b an optometrist shall consult with an ophthalmologist within days when any of the following occurs a the patient is experiencing documented progression of optic nerve damage or the patient develops documented and repeated progression of visual field loss on maximum tolerated topical medical therapy or b the patient develops or other secondary glaucoma", "status": 5, "party": 3}